- Home
- ABEO
as 12-20-2024 3:30pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 247.8M | IPO Year: | 1980 |
| Target Price: | $18.00 | AVG Volume (30 days): | 229.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.05 - $9.01 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | 147.52% |
| Revenue Growth (this year): | -97.09% | Revenue Growth (next year): | 18714.71% |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACCESSWIRE
25 days ago
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Zacks Small Cap Research
a month ago
ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…
GuruFocus.com
a month ago
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Associated Press Finance
a month ago
Abeona Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
a month ago
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire
2 months ago
Abeona Therapeutics® Announces Participation in November Investor Conferences
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.